Skip to main content
SpringerLink
Log in

Molecular Diagnostic in Prostate Cancer

  • Chapter
  • First Online:
Molecular Diagnostics in Cancer Patients

  • 958 Accesses

Abstract

Prostate cancer is an ideal tumor model for heterogeneity in almost every aspect. Its clinical, spatial, and morphological heterogeneity divided by the high-level molecular genetic diversity outline the complexity of this disease in the clinical and research settings. In this chapter, we summarize the main aspects of prostate cancer and its molecular diagnosis at different levels, with special attention given to the spatial heterogeneity within the prostate, and to understand its morphological heterogeneity, with respect to tumor grading and modern classifications. Prostate-specific antigen (PSA) screening is associated with a decline in prostate cancer related mortality. However, screening has also lead to over diagnosis and overtreatment of clinically insignificant tumors. Newly, certain national guidelines (eg, US Preventive Services Task Force) have recommended against PSA screening, which may lead to a reverse-stage migration, even though many prostate tumors are indolent at presentation, others are aggressive and are appropriate targets for treatment interventions. Molecular markers may help in discrimination of indolent and aggressive tumors, at the time of diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Ma S, Tang KH, Chan YP, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 2010;7:694–707. [PubMed: 21112564].

    Article  CAS  Google Scholar 

  2. Goodman OB, Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, Ma Y, Ward DC, Vogelzang NJ. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prev. 2009;18:1904–13.

    Article  CAS  Google Scholar 

  3. Feng DQ, Huang B, Li J, Liu J, Chen XM, Xu YM, Chen X, Zhang HB, Hu LH, Wang XZ. Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. Asian Pac J Cancer Prev. 2013;14:7501–8.

    Article  Google Scholar 

  4. Hessels D, Rittenhouse HG, Schalken JA. Molecular diagnosis in prostate cancer. 2009;6:255–61.

    Google Scholar 

  5. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45.

    Article  CAS  Google Scholar 

  6. Wu K, Hu M, Chen Z, Xiang F, Chen G, Yan W, Peng Q, Chen X. Asiatic acid enhances survival of human AC16 cardiomyocytes under hypoxia by upregulating miR-1290. IUBMB Life. 2017;69(9):660–7.

    Article  CAS  Google Scholar 

  7. Hessvik NP, Phuyal S, Brech A, Sandvig K, Llorente A. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim Biophys Acta. 2012;1819:1154–63.

    Article  CAS  Google Scholar 

  8. Zhao N, Yu H, Yu H, Sun M, Zhang Y, Xu M, Gao W. MiRNA-711-SP1-collagen-I pathway is involved in the anti-fibrotic effect of pioglitazone in myocardial infarction. Sci China Life Sci. 2013;56:431–9.

    Article  CAS  Google Scholar 

  9. Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015;67:33–41.

    Article  CAS  Google Scholar 

  10. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, Santella RM. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012;72:1469–77.

    Article  CAS  Google Scholar 

  11. Liao A, Gao Tan LC, Zhou W, Hu H. RASSF1A inhibits gastric cancer cell proliferation by miR-711-mediated downregulation of CDK4 miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. expression. Oncotarget. 2016;7:5842.

    PubMed  PubMed Central  Google Scholar 

  12. Jackson RJ, Standart N. How do microRNAs regulate gene expression. Sci STKE. 2007;(367):re1. Kumar A. Epidemiology of prostate cancer in India. Meta Gene. 2014;29:596–605.

    Google Scholar 

  13. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate-resistance and novel therapeutic approaches. Oncogene. 2013;32:5501.

    Article  CAS  Google Scholar 

  14. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum. Clin Cancer Res. 2013;19(13):3600–10.

    Article  CAS  Google Scholar 

  15. Ueno K, Hirata H, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, et al. microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer. 2013;108:1659–67.

    Article  CAS  Google Scholar 

  16. Lin M, Shi C, Lin X, Pan J, Shen S, Xu Z, Chen Q. sMicroRNA-1290 inhibits cells proliferation and migration by targeting FOXA1 in gastric cancer cells. Gene. 2016;582:137–42.

    Article  CAS  Google Scholar 

  17. Yang H, Li Q, Zhao W, Yuan D, Zhao H, Zhou Y. miR-329 suppresses the growth and motility of neuroblastoma by targeting KDM1A. FEBS Lett. 2014;588:192–7.

    Article  CAS  Google Scholar 

  18. Abd Elmageed ZY, Yang Y, Thomas R, Ranjan M, Mondal D. Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells. 2014;32:983–97.

    Article  CAS  Google Scholar 

  19. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.

    Article  CAS  Google Scholar 

  20. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68:6162–70.

    Article  CAS  Google Scholar 

  21. Miao Y, Zheng W, Li N, Su Z, Zhao L, Zhou H, Jia L. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway. Sci Rep. 2017;7:41942. https://doi.org/10.1038/srep41942.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126:1166–76.

    CAS  PubMed  Google Scholar 

  23. Ralfkiaer U, Hagedorn PH, Bangsgaard N, Løvendorf MB, Ahler CB, Svensson L, Kopp KL, Vennegaard MT, Lauenborg B, Zibert JR, Krejsgaard T. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood. 2011;118:5891–900.

    Article  CAS  Google Scholar 

  24. Ramalho-Carvalho J, Graça I, Gomez A, Oliveira J, Henrique R, Esteller M, et al. Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer. J Hematol Oncol. 2017;10:43.

    Article  Google Scholar 

  25. Stuopelytė K, Daniūnaitė K, Jankevičius F, Jarmalaitė S. Detection of miRNAs in urine of prostate cancer patients. Medicina. 2016;52:116–24.

    Article  Google Scholar 

  26. Rizos E, Siafakas N, Katsantoni E, Skourti E, Salpeas V, Rizos I, et al. Let-7, Mir-98 and Mir-181 as biomarkers for cancer and schizophrenia. PLoS One. 2015;10:e0123522.

    Article  Google Scholar 

  27. Sabirzhanov B, Stoica BA, Zhao Z, Loane DJ, Wu J, Dorsey SG, Faden AI. miR-711 upregulation induces neuronal cell death after traumatic brain injury. Cell Death Differ. 2016;23:654–68.

    Article  CAS  Google Scholar 

  28. Sarver AL, Li L, Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res. 2010;70:9570–80.

    Article  CAS  Google Scholar 

  29. Mihelich BL, Khramtsova EA, Arva N, Vaishnav A, Johnson DN, Giangreco AA, et al. MiR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem. 2011;286:44503–11.

    Article  CAS  Google Scholar 

  30. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8.

    Article  Google Scholar 

  31. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725–32.

    Article  Google Scholar 

  32. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.

    Article  Google Scholar 

  33. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT. miR-21: an androgen receptor–regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009;69:7165–9.

    Article  CAS  Google Scholar 

  34. Trang P, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics. Oncogene. 2008;27:S52–7.

    Article  CAS  Google Scholar 

  35. Li W, Liang J, Zhang Z, Lou H, Zhao L, Xu Y, Ou R. MicroRNA-329-3p targets MAPK1 to suppress cell proliferation, migration and invasion in cervical cancer. Oncol Rep. 2017;37:2743–50.

    Article  CAS  Google Scholar 

  36. Daniel R, Wu Q, Williams V, Clark G, Guruli G, Zehner Z. A panel of microRNAs as diagnostic biomarkers for the identification of prostate cancer. Int J Mol Sci. 2017;18:1281.

    Article  Google Scholar 

  37. Xiong F, Wu C, Chang J, Yu D, Xu B, Yuan P, Zhai K, Xu J, Tan W, Lin D. Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer. Cancer Res. 2011;71:5175–81.

    Article  CAS  Google Scholar 

  38. Xu L, Qi X, Duan S, Xie Y, Ren X, Chen G, et al. MicroRNAs: potential biomarkers for disease diagnosis. Biomed Mater Eng. 2014;24:3917–25.

    PubMed  Google Scholar 

  39. Zhang C, Liu J, Tan C, Yue X, Zhao Y, Peng J, Wang X, Laddha SV, Chan CS, Zheng S, Hu W. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis. Oncotarget. 2016;7:8783.

    PubMed  PubMed Central  Google Scholar 

  40. Ye L, Jiang T, Shao H, Zhong L, Wang Z, Liu Y, Tang H, Qin B, Zhang X, Fan J. miR-1290 is a biomarker in DNA-mismatch-repair-deficient colon cancer and promotes resistance to 5-fluorouracil by directly targeting hMSH2. Mol Ther Nucleic Acids. 2017;7:453–64.

    Article  CAS  Google Scholar 

  41. Liu R, Zhou Z, Huang J, Chen C. PMEPA1 promotes androgen receptor-negative prostate cell proliferation through suppressing the Smad3/4-c-Myc-p21 Cip1 signaling pathway. J Pathol. 2004;223:683–94.

    Article  Google Scholar 

  42. Hu JY, Yi W, Zhang MY, Xu R, Zeng LS, Long XR, Zhou XM, Zheng XF, Kang Y, Wang HY. MicroRNA-711 is a prognostic factor for poor overall survival and has an oncogenic role in breast cancer. Oncol Lett. 2016;11:2155–63.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, King George’s Medical University, Lucknow, Uttar Pradesh, India

    Mohammad Kaleem Ahmad, Soumya Srivastava & Abbas Ali Mahdi

Authors
  1. Mohammad Kaleem Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soumya Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abbas Ali Mahdi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Kaleem Ahmad .

Editor information

Editors and Affiliations

  1. Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, India

    Kamla Kant Shukla

  2. Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, India

    Praveen Sharma

  3. Department of Surgical Oncology, All India Institute of Medical Sciences, Jodhpur, India

    Sanjeev Misra

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ahmad, M.K., Srivastava, S., Mahdi, A.A. (2019). Molecular Diagnostic in Prostate Cancer. In: Shukla, K., Sharma, P., Misra, S. (eds) Molecular Diagnostics in Cancer Patients. Springer, Singapore. https://doi.org/10.1007/978-981-13-5877-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-5877-7_12

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-5876-0

  • Online ISBN: 978-981-13-5877-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation